<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-180" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Catheter Management of Aortic Valve Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brown</surname>
            <given-names>Kristen N.</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lee</surname>
            <given-names>Lawrence S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kanmanthareddy</surname>
            <given-names>Arun</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristen Brown declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lawrence Lee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arun Kanmanthareddy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-180.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Aortic valve disease is one of the most common valvular disorders in the United States and worldwide. Transcatheter management is emerging as a relevant approach as it allows for less invasive treatment of these valvular diseases when compared to traditional open heart surgery. This article describes the technique of transcatheter aortic valve replacement (TAVR), its indications, contraindications and highlights the role of the an interprofessional team in the management of patients with aortic valve disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the technique of transcatheter aortic valve replacement (TAVR).</p></list-item><list-item><p>Recall the indications for transcatheter aortic valve replacement (TAVR).</p></list-item><list-item><p>Summarize the complications of transcatheter aortic valve replacement (TAVR).</p></list-item><list-item><p>Outline the importance of improving care coordination among the an interprofessional Heart Team to enhance the delivery of care for patients with aortic valve disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=180&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=180">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-180.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Aortic valve disease, specifically aortic valve stenosis, is one of the most common valvular disorders in the United States and worldwide. While traditional aortic valve replacement via open heart surgery was historically the preferred--and only--definitive treatment option, transcatheter therapy now plays a significant role. Since the first reported case of transcather aortic valve replacement (TAVR) in a human in 2002, TAVR has evolved rapidly and now has become the preferred first-line treatment option for many patients with aortic stenosis.<xref ref-type="bibr" rid="article-180.r1">[1]</xref>&#x000a0; While the earliest TAVR patients were those deemed either prohibitive or very high risk for surgical aortic valve replacement (SAVR), the use of TAVR has expanded to include those who are intermediate and low risk.&#x000a0; The evolution has TAVR has encountered numerous pitfalls and technical modifications that have improved safety and efficacy.<xref ref-type="bibr" rid="article-180.r2">[2]</xref>&#x000a0; Landmark trials including the PARTNER 1 and PARTNER 2 studies have demonstrated the benefits of TAVR compared to medical management and SAVR. We describe here an overview of TAVR for aortic valve stenosis.</p>
      </sec>
      <sec id="article-180.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>The aortic valve separates the left ventricular outflow tract from the aortic root. It is generally a trileaflet valve composed of three distinct leaflets: the left coronary, right coronary, and non coronary leaflets. The aortic valve annulus is interconnected with the fibrous skeleton of the heart and is in continuity with the aorto-mitral curtain. The conduction system resides usually underneath the right coronary cusp extending towards the right-non commissure. In a small proportion of patients, the aortic valve is composed of two leaflets, leading to a bicuspid aortic valve.</p>
      </sec>
      <sec id="article-180.s4" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>TAVR Indications:</bold>
</p>
        <p>Current guidelines for TAVR include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Intermediate to prohibitive surgical risk patients with severe AS&#x000a0;(class I recommendation level B evidence)</p>
          </list-item>
          <list-item>
            <p>A valve-in-valve procedure for a failed prior bioprosthetic valve (class I recommendation, level B evidence)</p>
          </list-item>
        </list>
        <p>In mid-2019 the US FDA approved TAVR for low surgical risk patients. While society guidelines have not yet included this patient population in TAVR indications and practice guidelines (as of the time of this writing), we expect indications to expand to include these patients. Currently, guidelines&#x000a0;recommend SAVR for these patients if the patient is a surgical candidate. TAVR is not approved for use in aortic valve insufficiency (AI), although there have been reports of off-label use of TAVR in these patients.<xref ref-type="bibr" rid="article-180.r3">[3]</xref>&#x000a0;However, several studies are now&#x000a0;being conducted&#x000a0;to challenge this recommendation.<xref ref-type="bibr" rid="article-180.r4">[4]</xref>&#x000a0;</p>
        <p>
<bold>Balloon Aortic Valvuloplasty Indications:</bold>
</p>
        <p>This procedure was first introduced in 1986 as a non-invasive option for the treatment of aortic stenosis. Unfortunately due to the high failure rate with early restenosis and poor long term survival rates the procedure is rarely performed. Typically, this procedure is offered as a palliative option for patients with contraindications to TAVR or SAVR. Occasionally, it is offered to hemodynamically unstable patients as a bridge to SAVR or TAVR intervention. BAV is often performed at the time of TAVR to aid with valve implantation.</p>
      </sec>
      <sec id="article-180.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>TAVR Contraindications:</bold>
</p>
        <p>There are several contraindications to the use of TAVR. It is not recommended for any patient with a life expectancy under 12 months. Other contraindications include the absence of a Heart Team on-site, lack of cardiac surgical backup on-site, and other major co-morbidities that would limit post-operative quality of life such as profound dementia. Other factors&#x000a0;for consideration would include a myocardial infarction less than one month before, a severe pulmonary disease, such as pulmonary hypertension with right ventricular dysfunction, severely depressed left ventricular function less than 20% ejection fraction, abnormal size of native aortic annulus&#x000a0;less than 18 or larger than 25 mm. Also, the presence of an intracardiac mass, thrombus or vegetation,&#x000a0;intracardiac anatomy preventing&#x000a0;successful catheterization, or severe mitral regurgitation or insufficiency should be considered. In addition, patients unable to tolerate anticoagulation,&#x000a0;stroke/TIA within six months of procedure, patients requiring emergent surgical intervention, patients on dialysis, those with elevated serum creatinine higher than 3 mg/dL, congenital&#x000a0;bicuspid, unicuspid, or noncalcified aortic valve, hypertrophic cardiomyopathy (HOCM), significant aortic disease, or the presence of mixed aortic valve disease. There is debate on the feasilibity of TAVR in patients with mixed stenosis/insufficiency.<xref ref-type="bibr" rid="article-180.r5">[5]</xref>-<xref ref-type="bibr" rid="article-180.r6">[6]</xref></p>
        <p>
<bold>BAV&#x000a0;Contraindications:</bold>
</p>
        <p>Contraindications for percutaneous aortic valve balloon valvuloplasty include moderate to severe aortic insufficiency, an intracardiac mass, active endocarditis, and the&#x000a0;presence of a contraindication to&#x000a0;anti-thrombolytic therapy in the perioperative setting.<xref ref-type="bibr" rid="article-180.r7">[7]</xref></p>
      </sec>
      <sec id="article-180.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>TAVR can be performed in either a hybrid operating room or catheterization laboratory. Fluoroscopy, transesophageal echocardiography (TEE), perfusion standby, and appropriate procedure-specific instrumentation (wires, catheters, introducers, surgical instruments) as per institution protocol are required.&#x000a0; BAV is generally performed in the catheterization laboratory with fluoroscopy and/or TEE.</p>
      </sec>
      <sec id="article-180.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>
<bold>TAVR Personnel</bold>
</p>
        <p>Current personnel requirements in the US for TAVR include a cardiac surgeon and interventional cardiologist performing the procedure jointly. Other intraoperative personnel necessary include anesthesia (preferably cardiac anesthesia) with TEE capability, perfusionist standby, and operating room/catheterization laboratory support staff including scrub technicians/nurses.</p>
        <p>
<bold>BAV Personnel</bold>
</p>
        <p>BAV personnel required for completion of this procedure include an interventional cardiologist trained in BAV and appropriate catheterization laboratory staff. Cardiac anesthesia with TEE capability is preferable.</p>
      </sec>
      <sec id="article-180.s8" sec-type="Preparation">
        <title>Preparation</title>
        <p>
<bold>TAVR Preparation</bold>
</p>
        <p>Heart Team evaluation of any proposed TAVR patient is required. This consists of an interprofessional group including interventional cardiology and cardiac surgery. There must be Heart Team consensus for recommending TAVR over SAVR. The Heart Team must also review all relevant procedural planning aspects including valve sizing and planned vascular access. Preoperative diagnostic studies include echocardiogram (TTE or TEE), coronary artery evaluation with angiography, and TAVR-protocol computed tomography (CT) scanning. These studies help to evaluate the severity of aortic valve disease, anatomy of the aortic valve and root apparatus, size of the annulus and aortic root sinuses, degree of valve calcification, vascular access options including the lower and upper extremities, and functional status of other cardiac structures including ventricular function. <xref ref-type="bibr" rid="article-180.r8">[8]</xref>&#x000a0;Valve sizing can be accomplished with the use of dedicated software programs such as 3Mensio to aid with precise measurement. Laboratory workup should include an assessment of the baseline kidney function, liver function, hemoglobin, glucose, and type and cross-match. A&#x000a0;pulmonary function test and arterial blood gas analysis may be performed in patients with known or suspected pulmonary disease. A detailed airway evaluation is crucial to assess if the patient will tolerate general anesthesia and to avoid&#x000a0;preventable complications.&#x000a0;A thorough review of the patient's preoperative medications should also&#x000a0;be done.</p>
        <p>The patient is instructed to continue medications as they would for any other surgical procedure. Antiplatelet agents such as aspirin and clopidogrel may be already part of a patient&#x02019;s list of drugs, or they may be newly administered before the procedure. Aspirin in a dose of 75 to 300 mg should be delivered before the procedure if there are no contraindications to the use.<xref ref-type="bibr" rid="article-180.r9">[9]</xref>&#x000a0;Currently, there are no standardized postoperative antiplatelet use protocols, although many centers will start dual antiplatelet therapy for a limited duration postoperatively. On the day of the operation, approximately one hour before the procedure, pretreatment with intravenous antibiotics should be administered. There are no guidelines for post-operative antibiotic therapy, but some reports in the literature report prophylactic antibiotics for three to seven days following the procedure.</p>
        <p>
<bold>BAV Preparation</bold>
</p>
        <p>Prior to BAV a TTE is performed to assess the anatomy and severity of the AV disease. The aortic valve area and the mean transaortic valve gradient are noted. A coronary angioplasty is also performed prior to BAV and in the evaluate for and treat for coronary artery disease.</p>
      </sec>
      <sec id="article-180.s9" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>
<bold>TAVR Technique</bold>
</p>
        <p>The most important aspects to decide prior to the day of surgery is the valve size and vascular access. Various approaches include transfemoral, transaxillary, transapical, transaortic, and transcarotid.<xref ref-type="bibr" rid="article-180.r10">[10]</xref>&#x000a0;<xref ref-type="bibr" rid="article-180.r11">[11]</xref>&#x000a0;Percutaneous transfemoral approach is the most common and least invasive, while other approaches must be considered if the lower extremity or iliac vessels are of inadequate size, excessively tortuous, or heavily calcified. Of the alternative approaches, the transaxillary is the next most common.</p>
        <p>For the transfemoral approach, the vessels can be accessed either percutaneously or via open surgical cutdown. For the percutaneous route, the contralateral common femoral artery and vein are accessed and small caliber sheaths (such as 5 Fr and 6 Fr) are placed. A temporary pacing wire is inserted through this venous access and positioned into the right heart for pacing during valve deployment. A pigtail catheter is placed via this arterial access and positioned in one of the aortic sinus cusps. The operative side common femoral artery is then accessed using fluoroscopic guidance and a micropuncture needle. Two pre-deployed percutaneous vessel closure suture devices are placed for future use. Exchange length guidewires and catheters are then placed per institutional routine. Heparin is administered. The aortic valve is crossed with a guidewire and then exchanged to a soft wire over an exchange catheter. The delivery sheath (if the selected TAVR device uses a sheath) is inserted. The new device is loaded onto the delivery device and appropriate orientation is confirmed. BAV can be performed now if desired. The TAVR valve and delivery device are then inserted and positioned appropriately across the aortic annulus under fluoroscopy. Depending on the specific valve type, rapid ventricular pacing may be necessary. Self-expanding valve prostheses may not required rapid pacing. The valve is then deployed under fluoroscopic guidance. Once deployed, TEE is performed to evaluate positioning, valve function, and assess for paravalvular leak. If TEE shows acceptable findings, the delivery device is then removed. All other catheters are removed sequentially. The temporary pacing wire can be removed or left in place if there is any concern for heart block or conduction abnormalities. The delivery sheath is removed and the pre-deployed suture closure devices are secured.&#x000a0;</p>
        <p>For the transaxillary approach, an infraclavicular incision is made and soft tissue dissected to expose the axillary artery. The brachial plexus structures are often overlying the artery in this location and must be clearly identified and gently retracted to avoid injury. Furthermore, the use of electrocautery in this area should be avoided again to minimize the risk of injury to the nerve structures. Once the artery is exposed, proximal and distal control are obtained. Heparin is given. Pursestring sutures are placed at the site of planned access. Once the artery is accessed and wire placed via Seldinger technique, the remainder of the procedure can proceed as listed above for Transfemoral approach.</p>
        <p>For the transpaical approach, an echocardiogram probe is placed on the left inframammary region to ascertain the exact location of the LV apex. An inframammary skin incision is made and soft tissue dissected to expose the intercostal space. A finder needle can be used to confirm location. The intercostal space and pericardium are opened to expose the LV apex. A pursestring suture is placed and LV cavity accessed using Seldinger technique. One note of caution for this approach: the valve must be loaded in the appropriate orientation. The orientation for the transapical approach is opposite that of all other approaches since the access direction is antegrade.</p>
        <p>The transaortic approach requires an upper hemi-sternotomy to expose adequate ascending aorta. A pursestring is placed and aorta accessed again using Seldinger technique. The remainder of the procedure proceeds as described above.</p>
        <p>
<bold>BAV Technique</bold>
</p>
        <p>Access is obtained similar to the TAVR procedure described above. After obtaining access, a balloon catheter is introduced and positioned across the stenotic aortic valve. Aortic valvuloplasty is then performed with balloon inflation with the aim to increase aortic valve area (AVA) and reduce transaortic pressure gradient.&#x000a0;To obtain the mean transaortic pressure gradient,&#x000a0;a pigtail catheter is used to measure this gradient before and after valvuloplasty. The goal of this procedure is to reduce the pressure gradient by at least a half. If the initial attempt fails to achieve the gradient change then balloon inflation can be repeated.&#x000a0;<xref ref-type="bibr" rid="article-180.r12">[12]</xref></p>
      </sec>
      <sec id="article-180.s10" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>TAVR Complications</bold>
</p>
        <p>Studies have demonstrated vascular complications, arrhythmias/conduction abnormalities, and stroke were the most common major complications following TAVR.<xref ref-type="bibr" rid="article-180.r13">[13]</xref>&#x000a0;Death, coronary obstruction, aortic root rupture, and major hemorrhage were also reported, although less frequently than the former.<xref ref-type="bibr" rid="article-180.r14">[14]</xref>&#x000a0;According to a study done&#x000a0;by Ribeiro and colleagues, the risk of coronary artery obstruction was four times higher in patients following valve-in-valve TAVR.<xref ref-type="bibr" rid="article-180.r15">[15]</xref>&#x000a0;Other documented complications include worsening aortic stenosis or regurgitation, mispositioning of the valve, device embolus, kidney disease or myocardial infarction. PARTNER 2 Trial results showed a significantly higher rate of kidney disease with the use of TAVR versus SAVR.<xref ref-type="bibr" rid="article-180.r16">[16]</xref></p>
        <p>
<bold>BAV Complications</bold>
</p>
        <p>BAV does not improve long term survival. Therefore, it is normally only recommended as a palliative measure or a bridge to TAVR or SAVR. Other common complications following BAV including prolonged hospitalizations, the requirement for blood transfusions, acute kidney injury and/or failure, serious vascular complications (most common), profound hypotension, cardiac tamponade, permanent pacemaker, moderate to severe aortic regurgitation, coronary occlusion or dissection, stroke, or intraprocedural death.&#x000a0;<xref ref-type="bibr" rid="article-180.r17">[17]</xref></p>
      </sec>
      <sec id="article-180.s11" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>TAVR</bold>
</p>
        <p>The advent of the transcatheter approach in managing aortic valve disease was a monumental turning point in the field of cardiovascular disease. TAVR has provided a treatment option for those deemed prohibitive risk for traditional SAVR, and offers a much less invasive and morbid option for those at lower surgical risk.&#x000a0;&#x000a0;</p>
        <p>
<bold>BAV</bold>
</p>
        <p>The BAV was the first transcatheter intervention introduced for the treatment of severe aortic valve disease. Although it is no longer recommended as monotherapy, except as a palliative measure, it opened the door for more advanced therapies to be developed such as the formerly discussed TAVR. BAV is still performed today on patients as a bridge therapy for TAVR or SAVR and for palliative care as no long term survival benefit post-procedure has been established.</p>
      </sec>
      <sec id="article-180.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Percutaneous transcatheter management of aortic valve disease requires a skilled interprofessional team of healthcare professionals that includes a cardiac nurse, laboratory technologists, a pharmacist and some physicians in different specialties. Without proper pre-operative, intra-operative, and post-operative management life-threatening&#x000a0;complications can and will occur.&#x000a0;Therefore, it is imperative that the interprofessional team works as a unit with reliable communication to optimize patient-centered care. From the moment an aortic valve defect is identified, the discovering clinician has a&#x000a0;responsibility to coordinate&#x000a0;care including&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Obtain an echocardiogram, electrocardiography, chest radiograph, and detailed physical exam including general labs</p>
          </list-item>
          <list-item>
            <p>Monitor the patient for signs and symptoms of respiratory distress, cardiac arrhythmias, and&#x000a0;cardiovascular collapse</p>
          </list-item>
          <list-item>
            <p>Consult with the interventional cardiologist and cardiothoracic surgeon to assess the need for catheter versus surgical intervention [level 1]</p>
          </list-item>
          <list-item>
            <p>Consult with the structuralist about imaging tests to ensure that they&#x000a0;meet the requirements for surgical or catheter management</p>
          </list-item>
          <list-item>
            <p>Consult with the intensivist about ICU care and monitoring while in the hospital with the assistance of cardiac specialty nurses trained nurses assisting with coordination of care, family education, and reporting untoward changes in vital signs and arrhythmias.</p>
          </list-item>
          <list-item>
            <p>The cardiac pharmacist specialty should assist with checking for drug-drug interactions, appropriate dosing, and assisting the team with monitoring therapeutic effect.</p>
          </list-item>
        </list>
        <p>The management of aortic valve disease is a dynamic, ever-changing field. New technology comes up every day. It is crucial for the team to be up-to-date with the new upcoming technology and guidelines.&#x000a0;</p>
      </sec>
      <sec id="article-180.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=180&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=180">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/180/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=180">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-180.s14">
        <fig id="article-180.image.f1" position="float" orientation="portrait">
          <caption>
            <p>The Aortic Valve. The aortic valve resides centrally between the ascending aorta and the left ventricular outflow tract. Anatomist90, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/w/index.php?curid=17215093">Public Domain</ext-link>, via Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="The__Aortic__Valve" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-180.s15">
        <fig id="article-180.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Recommendations for Aortic Valve Replacement Table. The recommendations, classes of recommendations, and level of evidence for aortic valve replacement are detailed in the table. Contributed by S Harika, MBBS</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Aortic__Valve__Repair" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-180.s16">
        <fig id="article-180.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Indications for Aortic Valve Replacement. Contributed by S Harika Pujari, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Symptomatic" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-180.s17">
        <title>References</title>
        <ref id="article-180.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cribier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eltchaninoff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borenstein</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tron</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Derumeaux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Anselme</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Laborde</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description.</article-title>
            <source>Circulation</source>
            <year>2002</year>
            <month>Dec</month>
            <day>10</day>
            <volume>106</volume>
            <issue>24</issue>
            <fpage>3006</fpage>
            <page-range>3006-8</page-range>
            <pub-id pub-id-type="pmid">12473543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Salinger</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous balloon aortic valvuloplasty: antegrade transseptal vs. conventional retrograde transarterial approach.</article-title>
            <source>Catheter Cardiovasc Interv</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>314</fpage>
            <page-range>314-21</page-range>
            <pub-id pub-id-type="pmid">15736255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelghani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavalcante</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>de Winter</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Sarmento-Leite</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mangione</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Abizaid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lemos</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Serruys</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>de Brito</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Transcatheter aortic valve implantation for mixed versus pure stenotic aortic valve disease.</article-title>
            <source>EuroIntervention</source>
            <year>2017</year>
            <month>Nov</month>
            <day>20</day>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>1157</fpage>
            <page-range>1157-1165</page-range>
            <pub-id pub-id-type="pmid">28691910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barker</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Reardon</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Should TAVR Replace Surgery for Aortic Stenosis in Low- to Intermediate-Risk Patients?</article-title>
            <source>Can J Cardiol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>1124</fpage>
            <page-range>1124-1128</page-range>
            <pub-id pub-id-type="pmid">28843323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lef&#x000e8;vre</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Who is the right patient for TAVI?</article-title>
            <source>J Cardiol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>178</fpage>
            <page-range>178-81</page-range>
            <pub-id pub-id-type="pmid">24332753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rezq</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montorfano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Covello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive multidisciplinary patient assessment and selection before TAVI procedure.</article-title>
            <source>Minerva Cardioangiol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-91</page-range>
            <pub-id pub-id-type="pmid">24686996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olasi&#x00144;ska-Wi&#x0015b;niewska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trojnarska</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Grygier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lesiak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grajek</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous balloon aortic valvuloplasty in different age groups.</article-title>
            <source>Postepy Kardiol Interwencyjnej</source>
            <year>2013</year>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-7</page-range>
            <pub-id pub-id-type="pmid">24570692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Fassl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Augoustides</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Transcatheter aortic valve replacement--part 3: the central role of perioperative transesophageal echocardiography.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>698</fpage>
            <page-range>698-710</page-range>
            <pub-id pub-id-type="pmid">22578977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grube</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buellesfeld</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gerckens</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Linke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wenaweser</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sauren</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zickmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Iversen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Felderhoff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cartier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bonan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2007</year>
            <month>Jul</month>
            <day>03</day>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-76</page-range>
            <pub-id pub-id-type="pmid">17601548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dapunt</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Luha</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ebner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sonecki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spadaccio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>FW</given-names>
              </name>
            </person-group>
            <article-title>New Less Invasive Approach for Direct Aortic Transcatheter Aortic Valve Replacement Using Novel CoreVista Transcervical Access System.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2016</year>
            <month>Apr</month>
            <day>11</day>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>750</fpage>
            <page-range>750-3</page-range>
            <pub-id pub-id-type="pmid">27056316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walther</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dewey</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Borger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kempfert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Becht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Transapical aortic valve implantation: step by step.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>87</volume>
            <issue>1</issue>
            <fpage>276</fpage>
            <page-range>276-83</page-range>
            <pub-id pub-id-type="pmid">19101311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kogoj</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Devjak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bunc</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Balloon aortic valvuloplasty (BAV) as a bridge to aortic valve replacement in cancer patients who require urgent non-cardiac surgery.</article-title>
            <source>Radiol Oncol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-6</page-range>
            <pub-id pub-id-type="pmid">24587781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rod&#x000e9;s-Cabau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Neurological Complications Following Aortic Valve Replacement: TAVR Better Than SAVR, But Room for Improvement.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>30</day>
            <volume>72</volume>
            <issue>18</issue>
            <fpage>2120</fpage>
            <page-range>2120-2122</page-range>
            <pub-id pub-id-type="pmid">30360821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Tuzcu</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Makkar</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dewey</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kapadia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Babaliaros</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thourani</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Corso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pichard</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Bavaria</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Akin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <collab>PARTNER Trial Investigators</collab>
            </person-group>
            <article-title>Transcatheter versus surgical aortic-valve replacement in high-risk patients.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Jun</month>
            <day>09</day>
            <volume>364</volume>
            <issue>23</issue>
            <fpage>2187</fpage>
            <page-range>2187-98</page-range>
            <pub-id pub-id-type="pmid">21639811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ribeiro</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Makkar</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Kapadia</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Kodali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamburino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barbanti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jilaihawi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Paradis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>de Brito</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>C&#x000e1;novas</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cheema</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>de Jaegere</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>del Valle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chiam</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pradas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salgado-Fern&#x000e1;ndez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sarmento-Leite</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Toeg</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Velianou</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zajarias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Babaliaros</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dager</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Manoharan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lerakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pichard</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dumont</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Larose</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pasian</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Nombela-Franco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Urena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tuzcu</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Amat-Santos</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Leipsic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rod&#x000e9;s-Cabau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Oct</month>
            <day>22</day>
            <volume>62</volume>
            <issue>17</issue>
            <fpage>1552</fpage>
            <page-range>1552-62</page-range>
            <pub-id pub-id-type="pmid">23954337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beohar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kirtane</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Blackstone</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Waksman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Minha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Suri</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kodali</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Trends in Complications and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Replacement: Experience From the PARTNER Continued Access Registry.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2016</year>
            <month>Feb</month>
            <day>22</day>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>355</fpage>
            <page-range>355-363</page-range>
            <pub-id pub-id-type="pmid">26803420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-180.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Dor</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pichard</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Satler</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Gaglia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Weissman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maluenda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wakabayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Torguson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okubagzi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Waksman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Complications and outcome of balloon aortic valvuloplasty in high-risk or inoperable patients.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>11</issue>
            <fpage>1150</fpage>
            <page-range>1150-6</page-range>
            <pub-id pub-id-type="pmid">21087751</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
